• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts

    Thumbnail
    View/ Open
    out (7).pdf (946.9Kb)

    Show full item record
    Author
    Tefferi, Ayalew; Mudireddy, Mythri; Mannelli, Francesco; Begna, Kebede H.; Patnaik, Mrinal M.; Hanson, Curtis A.; Ketterling, Rhett P.; Gangat, Naseema; Yogarajah, Meera; De Stefano, Valerio; Passamont, Francesco; Rosti, Vittorio; Finazzi, Maria Chiara; Rambaldi, Alessandro; Bosi, Alberto; Guglielmelli, Paola; Pardanani, Animesh; Vannucchi, Alessandro M.
    Abstract
    A total of 410 patients with blast phase myeloproliferative neoplasm (MPN-BP) were retrospectively reviewed: 248 from the Mayo Clinic and 162 from Italy. Median survival was 3.6 months, with no improvement over the last 15 years. Multivariable analysis performed on the Mayo cohort identified high risk karyotype, platelet count < 100 × 109 /L, age > 65 years and transfusion need as independent risk factors for survival. Also in the Mayo cohort, intensive chemotherapy resulted in complete remission (CR) or CR with incomplete count recovery (CRi) rates of 35 and 24%, respectively; treatment-specified 3-year/5-year survival rates were 32/10% for patients receiving allogeneic stem cell transplant (AlloSCT) (n = 24), 19/13% for patients achieving CR/CRi but were not transplanted (n = 24), and 1/1% in the absence of both AlloSCT and CR/CRi (n = 200) (p < 0.01). The survival impact of AlloSCT (HR 0.2, 95% CI 0.1–0.3), CR/CRi without AlloSCT (HR 0.3, 95% CI 0.2–0.5), high risk karyotype (HR 1.6, 95% CI 1.1–2.2) and platelet count < 100 × 109 /L (HR 1.6, 95% CI 1.1–2.2) were confirmed to be interindependent. Similar observations were made in the Italian cohort. The current study identifies the setting for improved short-term survival in MPN-BP, but also highlights the limited value of current therapy, including AlloSCT, in securing long-term survival.
    URI
    http://hdl.handle.net/10342/8369
    Date
    2018-02-02
    Citation:
    APA:
    Tefferi, Ayalew, & Mudireddy, Mythri, & Mannelli, Francesco, & Begna, Kebede H., & Patnaik, Mrinal M., & Hanson, Curtis A., & Ketterling, Rhett P., & Gangat, Naseema, & Yogarajah, Meera, & De Stefano, Valerio, & Passamont, Francesco, & Rosti, Vittorio, & Finazzi, Maria Chiara, & Rambaldi, Alessandro, & Bosi, Alberto, & Guglielmelli, Paola, & Pardanani, Animesh, & Vannucchi, Alessandro M.. (February 2018). Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. , (), - . Retrieved from http://hdl.handle.net/10342/8369

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Tefferi, Ayalew, and Mudireddy, Mythri, and Mannelli, Francesco, and Begna, Kebede H., and Patnaik, Mrinal M., and Hanson, Curtis A., and Ketterling, Rhett P., and Gangat, Naseema, and Yogarajah, Meera, and De Stefano, Valerio, and Passamont, Francesco, and Rosti, Vittorio, and Finazzi, Maria Chiara, and Rambaldi, Alessandro, and Bosi, Alberto, and Guglielmelli, Paola, and Pardanani, Animesh, and Vannucchi, Alessandro M.. "Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts". . . (), February 2018. May 29, 2023. http://hdl.handle.net/10342/8369.
    Chicago:
    Tefferi, Ayalew and Mudireddy, Mythri and Mannelli, Francesco and Begna, Kebede H. and Patnaik, Mrinal M. and Hanson, Curtis A. and Ketterling, Rhett P. and Gangat, Naseema and Yogarajah, Meera and De Stefano, Valerio and Passamont, Francesco and Rosti, Vittorio and Finazzi, Maria Chiara and Rambaldi, Alessandro and Bosi, Alberto and Guglielmelli, Paola and Pardanani, Animesh and Vannucchi, Alessandro M., "Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts," , no. (February 2018), http://hdl.handle.net/10342/8369 (accessed May 29, 2023).
    AMA:
    Tefferi, Ayalew, Mudireddy, Mythri, Mannelli, Francesco, Begna, Kebede H., Patnaik, Mrinal M., Hanson, Curtis A., Ketterling, Rhett P., Gangat, Naseema, Yogarajah, Meera, De Stefano, Valerio, Passamont, Francesco, Rosti, Vittorio, Finazzi, Maria Chiara, Rambaldi, Alessandro, Bosi, Alberto, Guglielmelli, Paola, Pardanani, Animesh, Vannucchi, Alessandro M.. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. . February 2018; (): . http://hdl.handle.net/10342/8369. Accessed May 29, 2023.
    Collections
    • Open Access

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback